Who is sponsoring NCT02782182?

NCT02782182 is sponsored by University of Chicago.

What drugs are being tested in NCT02782182?

Interventions in NCT02782182: FOLFIRINOX (oxaliplatin, leucovorin, irinotecan).

What condition does NCT02782182 study?

NCT02782182 studies Pancreatic Ductal Adenocarcinoma (PDAC).

Is NCT02782182 still recruiting?

NCT02782182 is currently terminated. Last updated 19 March 2019.

Last reviewed 2019-03-19 · How we verify

NCT02782182

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

Terminated Phase 1 Last updated 19 March 2019

What this trial tests

Phase 1 trial testing FOLFIRINOX (oxaliplatin, leucovorin, irinotecan) in Pancreatic Ductal Adenocarcinoma (PDAC) in 1 participant. Terminated before completion.

Timeline

28 June 2016

Primary endpoint
29 March 2018

29 March 2018

Quick facts

Lead sponsor	University of Chicago
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	28 June 2016
Primary completion	29 March 2018
Estimated completion	29 March 2018
Sites	1 location across United States

Drugs / interventions tested

FOLFIRINOX (oxaliplatin, leucovorin, irinotecan) — full drug profile →

Conditions studied

Pancreatic Ductal Adenocarcinoma (PDAC) — all drugs for Pancreatic Ductal Adenocarcinoma (PDAC) →

Sponsor

University of Chicago

Who can join

18 and older, any sex, with Pancreatic Ductal Adenocarcinoma (PDAC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see whether it is possible to give 8 doses of a combination of chemotherapy called FOLFIRINOX before surgery in subjects whose pancreas cancer can be removed with surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pancreatic Ductal Adenocarcinoma (PDAC)

Currently open trials in the same condition.

NCT07480928 — Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma · Phase 1, PHASE2 · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07030283 — Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis · Phase 1 · recruiting
NCT07235202 — A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarci · Phase 1, PHASE2 · recruiting
NCT07217717 — Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) · Phase 3 · recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02782182 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 19 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02782182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing